We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...
Eli Lilly’s latest TV ad, unveiled during the Grammys on Sunday night, highlights the importance of early diagnosis for ...
The Washington University trial comes as part of a larger platform study, which hopes to understand whether the disease can ...
Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...
An international trial is testing remternetug in young adults at genetic risk for early-onset Alzheimer’s. The study aims to ...
He also sardonically targeted co-host David Faber and said “Look I’m sure that when they discovered the cotton gin, and ...
Alzheimer’s disease has afflicted Hannah Richardson’s family for generations. A rare genetic mutation, passed down from her great-grandmother, has struck her relatives with the first signs of memory ...
Eli Lilly & Co. (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. Its products span oncology, ...
It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...
If you want stocks that you can buy and hold for not only years, but potentially the rest of your life, it's important to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback